<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2016-1S-20-24</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2247</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>РАСПРОСТРАНЕННОСТЬ МЕТАБОЛИЧЕСКОГО  СИНДРОМА У БОЛЬНЫХ ПСОРИАТИЧЕСКИМ  АРИТРИТОМ: ЕГО СВЯЗЬ С ВОСПАЛЕНИЕМ И СУБКЛИНИЧЕСКИМ   АТЕРОСКЛЕРОЗОМ</article-title><trans-title-group xml:lang="en"><trans-title>PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH PSORIATIC ARTHRITIS: ITS ASSOCIATION WITH INFLAMMATION AND SUBCLINICAL ATHEROSCLEROSIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркелова</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Markelova</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"><p>Markelova Evgenia</p></bio><email xlink:type="simple">evgenia-i.m@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коротаева</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Korotaeva</surname><given-names>T. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>D. S.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Логинова</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Loginova</surname><given-names>E. Yu.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глухова</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Glukhova</surname><given-names>S. I.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт ревматологии имени В.А. Насоновой, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>15</day><month>09</month><year>2016</year></pub-date><volume>54</volume><issue>1S</issue><issue-title>приложение 1</issue-title><fpage>20</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Маркелова Е.И., Коротаева Т.В., Новикова Д.С., Логинова Е.Ю., Глухова С.И., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Маркелова Е.И., Коротаева Т.В., Новикова Д.С., Логинова Е.Ю., Глухова С.И.</copyright-holder><copyright-holder xml:lang="en">Markelova E.I., Korotaeva T.V., Novikova D.S., Loginova E.Y., Glukhova S.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2247">https://rsp.mediar-press.net/rsp/article/view/2247</self-uri><abstract><p>Метаболический синдром (МС) является  совокупностью метаболических нарушений, приводящих к развитию сердечно-сосудистых заболеваний (ССЗ)  атеросклеротического генеза. Сочетание  у больных псориатическим артритом (ПсА) воспалительной активности и высокой  распространенности традиционных факторов риска (ФР) развития  ССЗ позволяет  отнести их к группе более высокого риска по сердечно-сосудистым осложнениям в сравнении с общей популяцией.</p><p>Цель исследования – оценить распространенность МС, а также его связь с воспалением и субклиническим атеросклерозом у больных ПсА.</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование включено  128 больных ПсА (женщин – 61,7%, мужчин – 38,3%), медиана возраста 43 [34; 49,5] лет, длительности  ПсА – 7 [3; 13] лет, длительности  псориаза  – 15 [6; 26] лет. Преобладали пациенты  с умеренной  (3,7≥DAS&gt;2,4) и высокой  (DAS&gt;3,7)  активностью заболевания: 33 (25,8%) и 74 (57,8%) соответственно. МС диагностирован на основании Национальных рекомендаций Российского кардиологического общества по кардиоваскулярной профилактике (2011). Для диагностики субклинического атеросклероза всем больным  проводили  ультразвуковую допплерографию (УЗДГ) сонных артерий.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. МС был диагностирован у 49 (38,3%) больных ПсА. Из критериев  МС чаще выявлялись: абдоминальное ожирение  – у 72 (56,3%) и дислипидемия [повышение уровня липопротеидов низкой плотности  (ЛПНП) – у 101 (78,9%), снижение  уровня липопротеидов высокой  плотности  (ЛПВП)  – у 65 (50,8%)]. Артериальная  гипертензия диагностирована у 32 (25%). Субклинический атеросклероз  по данным УЗДГ сонных артерий выявлен  у 65 (50,8%) больных.</p><p>Пациенты с МС были старше пациентов без МС (46 [43; 52] и 39 [31; 46] лет соответственно; p&lt;0,0001). Эти группы не различались по длительности  ПсА (15 [7; 29] и 15 [5,5; 25] лет; p=0,47).  У больных с МС были выше значения индекса DAS (4,4 [3,2; 5,6] и 3,6 [2,5; 4,7] соответственно; p=0,02), средняя толщина  комплекса интима–медиа (КИМ) (0,78 [0,72; 0,86] и 0,73 [0,66; 0,77] мм; p&lt;0,0001) и максимальная толщина  КИМ  (0,94 [0,84; 1,03] и 0,84 [0,75; 0,94] мм; p&lt;0,01). У них достоверно чаще выявлялись  признаки субклинического атеросклероза сонных артерий в сравнении с пациентами без МС – 33 (67,3%) и 32 (40,5%) соответственно (p=0,003).</p><p>Выявлена  статистически значимая  связь между толщиной КИМ  и ФР развития  ССЗ (компонентами МС): окружностью  талии (R=0,41; p&lt;0,0001), уровнем систолического артериального давления (R=0,41; p&lt;0,0001), ЛПНП (R=0,44, p&lt;0,0001), триглицеридов (R=0,36; p&lt;0,0001). Также выявлена корреляция между толщиной КИМ  и длительностью  ПсА (R=0,18; p&lt;0,03).</p></sec><sec><title>Заключение</title><p>Заключение. Таким образом,  у больных ПсА отмечена высокая распространенность МС, который  выявлен почти у 40% включенных  в исследование пациентов. Обнаружена  взаимосвязь активности ПсА с МС.</p><p>У больных ПсА при наличии  МС толщина  КИМ  была больше, чем при его отсутствии. Установлена  ассоциация между толщиной КИМ  и традиционными ФР ССЗ (компонентами МС), длительностью  ПсА, что позволяет предположить влияние  на процесс развития  ССЗ у больных ПсА как традиционных ФР ССЗ,  так и длительности  ПсА.</p></sec></abstract><trans-abstract xml:lang="en"><p>Metabolic syndrome (MS) is a cluster of metabolic disorders giving rise to atherosclerotic  cardiovascular diseases (CVD). The combination  of inflammatory activity and a high spread of traditional  risk factors (RF) for CVD in patients with psoriatic arthritis (PsA) permits them to be referred to as a higher cardiovascular risk group as compared to the general population.</p><sec><title>Objective</title><p>Objective: to estimate the spread of MS and its association with inflammation and subclinical atherosclerosis in patients with PsA.</p></sec><sec><title>Subjects and methods</title><p>Subjects and methods. This investigation enrolled 128 patients with PsA (61.7% women and 38.3% men); their median age was 43 [34; 49.5] years; the duration of PsA and psoriasis – 7 [3; 13] and 15 [6; 26] years, respectively). There was a preponderance of patients with moderate (3.7 ≥ DAS &gt; 2.4) and high (DAS &gt; 3.7) disease activity: 33 (25.8%) and 74 (57.8%), respectively. MS was diagnosed on the basis of the 2011 National  Guidelines of the Russian Cardiology Society for Cardiovascular Prevention.  All the patients underwent carotid Doppler ultrasound (CDU) for the diagnosis of subclinical atherosclerosis. </p></sec><sec><title>Results and discussion</title><p>Results and discussion. MS was diagnosed in 49 (38.3%) patients with PsA. The most common  MS criteria were abdominal  obesity in 72 (56.3%) and dyslipidemia [an elevation of low-density lipoproteins (LDL)  level in 101 (78.9%), and a decrease in high-density lipoproteins (HDL)  level in 65 (50.8)]. Hypertension was diagnosed in 32 (25%). 65 (50.8%) patients were found to have subclinical atherosclerosis,  as evidenced by CDU.</p><p>The patients with MS were older than those without this condition  (46 [43; 52] and 39 [31; 46] years, respectively; p &lt; 0.0001). These groups did not differ in PsA duration (15 [7; 29] and 15 [5.5; 25] years respectively; p = 0.47). The patients with MS had higher DAS values (4.4 [3.2; 5.6] and 3.6 [2.5; 4.7], respectively; p = 0.02); mean intima media thickness (IMT)  (0.78 [0.72; 0.86] and 0.73 [0.66; 0.77] mm; p &lt; 0.0001) and maximal IMT (0.94 [0.84; 1.03] and 0.84 [0.75; 0.94] mm; p &lt; 0.01). They were found to have significantly more often signs of subclinical carotid atherosclerosis than those without MS (33 (67.3%) and 32 (40.5%) patients, respectively; p = 0.003).</p><p>There was a statistically significant relationship between IMT and RF for CVD (MS components, such as waist circumference  (R = 0.41; p &lt;0.0001), systolic blood pressure (R = 0.41; p &lt; 0.0001), LDL (R = 0.44; p &lt; 0.0001), and triglycerides (R = 0.36; p &lt; 0.0001). There was also a correlation between IMT and PsA duration (R = 0.18; p &lt; 0.03).</p></sec><sec><title>Conclusion</title><p>Conclusion. Thus, the patients with PsA had a high prevalence of MS that was detected in almost 40% of them. There was a relationship of PsA activity to MS. In the PsA patients with MS, IMT was greater than in those without MS. An association was established between IMT and traditional  RF for CVD (MS components), PsA duration,  suggesting that both traditional  RF for CVD and PsA duration may affect the development process of CVD in patients with PsA.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>псориатический артрит</kwd><kwd>метаболический синдром</kwd><kwd>толщина  комплекса интима–медиа</kwd><kwd>воспаление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>psoriatic arthritis</kwd><kwd>metabolic syndrome</kwd><kwd>intima media thickness</kwd><kwd>inflammation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326-32. doi: 10.1136/annrheumdis-2014-205675</mixed-citation><mixed-citation xml:lang="en">Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326-32. doi: 10.1136/annrheumdis-2014-205675</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ahlehoff O, Gislason G, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147-57. doi: 10.1111/j.1365-2796.2010.02310.x</mixed-citation><mixed-citation xml:lang="en">Ahlehoff O, Gislason G, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147-57. doi: 10.1111/j.1365-2796.2010.02310.x</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Boehncke WH, Boehncke S, Tobin AM, et al. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303-7. doi: 10.1111/j.1600-0625.2011.01261.x</mixed-citation><mixed-citation xml:lang="en">Boehncke WH, Boehncke S, Tobin AM, et al. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303-7. doi: 10.1111/j.1600-0625.2011.01261.x</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;21;352(16):1685-95.</mixed-citation><mixed-citation xml:lang="en">Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;21;352(16):1685-95.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Eder L, Gladman DG. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015;7(5):187-95. doi: 10.1177/1759720X15591801</mixed-citation><mixed-citation xml:lang="en">Eder L, Gladman DG. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015;7(5):187-95. doi: 10.1177/1759720X15591801</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Karbach S, Croxford A, Oelze M, et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol. 2014;34(12):2658-68. doi: 10.1161/ATVBAHA.114.304108</mixed-citation><mixed-citation xml:lang="en">Karbach S, Croxford A, Oelze M, et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol. 2014;34(12):2658-68. doi: 10.1161/ATVBAHA.114.304108</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Miller I, Ellervik C, Yazdanyar S, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014-24. doi: 10.1016/j.jaad.2013.06.053</mixed-citation><mixed-citation xml:lang="en">Miller I, Ellervik C, Yazdanyar S, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014-24. doi: 10.1016/j.jaad.2013.06.053</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8(4):331-4. doi: 10.1089/met.2009.0124</mixed-citation><mixed-citation xml:lang="en">Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8(4):331-4. doi: 10.1089/met.2009.0124</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Labitigan M, Bahce-Altuntas A, Kremer JM, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(4):600-7. doi: 10.1002/acr.22185</mixed-citation><mixed-citation xml:lang="en">Labitigan M, Bahce-Altuntas A, Kremer JM, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(4):600-7. doi: 10.1002/acr.22185</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24(1):29-33. doi: 10.1161/01.ATV.0000099786.99623.EF</mixed-citation><mixed-citation xml:lang="en">Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24(1):29-33. doi: 10.1161/01.ATV.0000099786.99623.EF</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kontny E, Plebanczyk M, Lisowska B, et al. Comparison of rheumatoid articular adipose and synovial tissue reactivity to proinflammatory stimuli: contribution to adipocytokine network. Ann Rheum Dis. 2012;71(2):262-7. doi: 10.1136/annrheumdis-2011-200123</mixed-citation><mixed-citation xml:lang="en">Kontny E, Plebanczyk M, Lisowska B, et al. Comparison of rheumatoid articular adipose and synovial tissue reactivity to proinflammatory stimuli: contribution to adipocytokine network. Ann Rheum Dis. 2012;71(2):262-7. doi: 10.1136/annrheumdis-2011-200123</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Xue Y, Jiang L, Cheng Q, et al. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One. 2012;7(10):e46740. doi: 10.1371/journal.pone.0046740</mixed-citation><mixed-citation xml:lang="en">Xue Y, Jiang L, Cheng Q, et al. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One. 2012;7(10):e46740. doi: 10.1371/journal.pone.0046740</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Love T, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71(8):1273-7. doi: 10.1136/annrheumdis-2012-201299</mixed-citation><mixed-citation xml:lang="en">Love T, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71(8):1273-7. doi: 10.1136/annrheumdis-2012-201299</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Eder L, Thavaneswaran A, Chandran V, et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(5):813-7. doi: 10.1136/annrheumdis-2013-204448</mixed-citation><mixed-citation xml:lang="en">Eder L, Thavaneswaran A, Chandran V, et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(5):813-7. doi: 10.1136/annrheumdis-2013-204448</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Янышева АВ. Метаболические нарушения при псориатическом артрите. Сибирский медицинский журнал. 2009;85(2):25-8 [Yanysheva AV. Metabolic disorders in psoriatic arthritis. Sibirskii Meditsinskii Zhurnal. 2009;85(2):25-8 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Янышева АВ. Метаболические нарушения при псориатическом артрите. Сибирский медицинский журнал. 2009;85(2):25-8 [Yanysheva AV. Metabolic disorders in psoriatic arthritis. Sibirskii Meditsinskii Zhurnal. 2009;85(2):25-8 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chandran V, Schentag CT, Gladman DD. Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. J Rheumatol. 2008;35(10):2069-70.</mixed-citation><mixed-citation xml:lang="en">Chandran V, Schentag CT, Gladman DD. Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. J Rheumatol. 2008;35(10):2069-70.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization (WHO). Obesity: prevention and management of the global epidemic. Report of the WHO Consultation. WHO Tech Rep Ser. 2000;894(i-xii):1-253.</mixed-citation><mixed-citation xml:lang="en">World Health Organization (WHO). Obesity: prevention and management of the global epidemic. Report of the WHO Consultation. WHO Tech Rep Ser. 2000;894(i-xii):1-253.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Национальные рекомендации по кардиоваскулярной профилактике. Комитет экспертов РКО. Кардиоваскулярная терапия и профилактика. 2011;10(6)Прил. 2:1-64 [National guidelines on cardiovascular prevention. Committee of Experts of the Russian Society of Cardiology. Kardiovaskulyarnaya Terapiya i Profilaktika. 2011;10(6)Suppl. 2:1-64 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Национальные рекомендации по кардиоваскулярной профилактике. Комитет экспертов РКО. Кардиоваскулярная терапия и профилактика. 2011;10(6)Прил. 2:1-64 [National guidelines on cardiovascular prevention. Committee of Experts of the Russian Society of Cardiology. Kardiovaskulyarnaya Terapiya i Profilaktika. 2011;10(6)Suppl. 2:1-64 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ребров АП, Гайдукова ИЗ. Особенности дислипидемии при псориатическом артрите: взаимосвязь с атеросклерозом, факторами сердечно-сосудистого риска и системным воспалением. Саратовский научно-медицинский журнал. 2010;3(6):592-6 [Rebrov AP, Gaidukova IZ. Features of dyslipidemias in psoriatic arthritis: correlation with atherosclerosis, factors of cardiovascular risk and systemic inflammation. Saratovskii Nauchno-Meditsinskii Zhurnal. 2010;3(6):592-6 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Ребров АП, Гайдукова ИЗ. Особенности дислипидемии при псориатическом артрите: взаимосвязь с атеросклерозом, факторами сердечно-сосудистого риска и системным воспалением. Саратовский научно-медицинский журнал. 2010;3(6):592-6 [Rebrov AP, Gaidukova IZ. Features of dyslipidemias in psoriatic arthritis: correlation with atherosclerosis, factors of cardiovascular risk and systemic inflammation. Saratovskii Nauchno-Meditsinskii Zhurnal. 2010;3(6):592-6 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bhole V, Choi H, Burns L, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012;51:552-6. doi: 10.1093/rheumatology/ker349</mixed-citation><mixed-citation xml:lang="en">Bhole V, Choi H, Burns L, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012;51:552-6. doi: 10.1093/rheumatology/ker349</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ma C, Harskamp C, Armstrong E, et al. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol. 2013;168:486-95. doi: 10.1111/bjd.12101</mixed-citation><mixed-citation xml:lang="en">Ma C, Harskamp C, Armstrong E, et al. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol. 2013;168:486-95. doi: 10.1111/bjd.12101</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kwon G, Schroeder J, Amar M, et al. Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation. 2008;117:2919-27. doi: 10.1161/CIRCULATIONAHA.107.754614</mixed-citation><mixed-citation xml:lang="en">Kwon G, Schroeder J, Amar M, et al. Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation. 2008;117:2919-27. doi: 10.1161/CIRCULATIONAHA.107.754614</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Shlyankevich J, Mehta N, Krueger J, et al. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. Am J Med. 2014;127:1148-3. doi: 10.1016/j.amjmed.2014.08.008.</mixed-citation><mixed-citation xml:lang="en">Shlyankevich J, Mehta N, Krueger J, et al. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. Am J Med. 2014;127:1148-3. doi: 10.1016/j.amjmed.2014.08.008.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
